INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/552,568
Filing Date	October 11, 2005
First Named Inventor	Kishore, *et al.*
Group Art Unit	1651
Examiner Name	Unassigned

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
/S.H./	A1	4,526,888	July 2, 1985	Williams, *et al.*			
	A2	4,667,016	May 19, 1987	Lai, *et al.*			
	A3	4,703,008	October 27, 1987	Lin			
	A4	4,935,350	June 19, 1990	Patel, *et al.*			
	A5	4,987,121	January 22, 1991	Baertschi, *et al.*			
	A6	5,032,507	July 16, 1991	Yu, *et al.*			
	A7	5,104,653	April 14, 1002	Michalevicz			
	A8	5,106,760	April 21, 1992	Egrie			
	A9	5,354,934	Ocotber 11, 1994	Pitt, *et al.*			
	A10	5,476,653	December 19, 1995	Pitt, *et al.*			
	A11	5,482,924	January 9, 1996	Royet, *et al.*			
	A12	5,547,933	August 20, 1996	Lin			
	A13	5,621,080	April 15, 1997	Lin			
	A14	5,618,698	April 8, 1997	Lin			
	A15	5,661,125	August 26, 1997	Strickland			
	A16	5,756,349	May 26, 1998	Lin			
	A17	5,830,705	November 3, 1998	Souza			
	A18	5,885,574	March 23, 1999	Elliott			
	A19	5,597,562	January 28, 1997	Nomura, *et al.*			
	A20	5,955,422	September 21, 1999	Lin			
	A21	6,221,397 B1	April 24, 2001	Russell-Jones, *et al.*			
	A22	6,319,499	November 20, 2001	Elliott			
/S.H./	A23	6,784,154 B2	August 31, 2004	Westenfelder			

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document Country Code-NumAer-Kind Code	Date	Name	Translation Yes/No
/S.H./	A24	WO 01/66149 A2	09/13/01	Valentis, Inc.	

NON-PATENT DOCUMENTS

Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, PuAlisher, Relevant Pages, Date and Place of PuAlication)
/S.H./	A25	Abbate, M., *et al.*, "Proteinuria as a mediator of tubulointerstitial injury," Kidney Blood Press Res 22:37-46, 1999
/S.H./	A26	Anagnostou, A., *et al.*, "Factors which affect erythropoiesis in partially nephrectomized and sham-operated rats," Blood 48:425-433, 1976

Examiner Signature:	Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/552,568
Filing Date	October 11, 2005
First Named Inventor	Kishore, *et al.*
Group Art Unit	1651
Examiner Name	Unassigned

NON-PATENT DOCUMENTS

Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, PuAlisher, Relevant Pages, Date and Place of PuAlication)
/S.H./	A27	Bachmann, S., *et al.*, "Co-localization of erythropoietin messenger RNA and ecto-5'-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin," J. Histochem Chytochem 41:335-341, 1993
	A28	Bellizzi, V., *et al.*, "The impact of early normalization of haematocrit by erythropoietin on renal damage in the remnant kidney model, Nephrol Dial. Transplant 13:2210-2215, 1998
	A29	Browne, *et al.*, "Erythropoietin: Gene cloning, protein structure, and biological properties," Cold Spring Harbor Symposia on Quantitative Biology, L1:693-702, 1986
	A30	Burton, C., *et al.*, "The role of proteinuria in the progression of chronic renal failure," Am. J. Kidney Dis. 27:765-775, 1996
	A31	Carlini, R., *et al.*, "Recombinant human erythropoietin stimulates angiogenesis in vitro," Kidney, Int. 47:740-745, 1995
	A32	Dendorfer, U., "Molecular biology of cytokines, Art. Organs," 20:437-444, 1996
	A33	Donnelly, S., "Why is erythropoietin made in the kidney? The kidney functions as a critmeter," Am J. Kidney Dis. 38:415-425, 2001
	A34	Eddy, A.A., "Interstitial nephritis induced by protein overlaod proteinuria," Am. J. Pathol. 135:719-733, 1989
	A35	Eddy, A.A., "Molecular basis of renal fibrosis," Pediatr. Nephrol. 15:290-301, 2000
	A36	Eddy, A.A., "Role of cellular infiltrates in response to proteinuria," Am. J. Kidney Dis., 37:S25-S29, 2001
	A37	Ferrara, N., "Molecuar and biological properties of vascular endothelial growth factor, J. Mole. Med. 77:527-543, 1999
	A38	Gandi, R., *et al.*, "Immunolocalization of ecto-5'-nucleotidase in the kidney by a monoclonal antibody," Histochemistry 95:165-174, 1990
	A39	Ghielli, M., *et al.*, "Inflammatory cells in renal pathology," Néphrologie 19:59-67, 1998
	A40	Gleadle, J.M. *et al.*, "Induction of hypoxia-inducible factor-1 erythropoietin, vascular endothelial growth factor and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase," Blood 89:503-509, 1997
	A41	Ivan, M., *et al.*, "HIF alpha targeted for VHL-mediated destruction by praline hydroxylation: implications for O_2 sensing," Science 292:464-468, 2001
	A42	Jaakkola, P., *et al.*, "Targeting of HIF alpha to the von Hippel-Lindau urbiquitylation complex by O_2 regulated prolyl hydroxylation," Science 292:468-472, 2001
	A43	Jelkmann, W., "Erythropoietin: structure, control of production, and function," Physio. Rev. 72:449-489, 1992
V	A44	Johnson, D.W., "Human renal fibroblasts modulate proximal tubule cell growth and transport via the IGF-1 axis," Kidney Int. 52:1486-1496, 1997
/S.H./	A45	Kaissling, B., "Morphology of interstitial cells in the healthy kidney, Anat. Embryol. 193:303-318, 1996

Examiner Signature:	Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/552,568
Filing Date	October 11, 2005
First Named Inventor	Kishore, *et al.*
Group Art Unit	1651
Examiner Name	Unassigned

NON-PATENT DOCUMENTS

Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, PuAlisher, Relevant Pages, Date and Place of PuAlication)
/S.H./	A46	Keane, W.F.,"Proteinuria: its clinical importance and role in progressive renal disease, AM. J. Kidney Dis. 35:S97-S105, 2000
	A47	Kendall, R.G., "Erythropoietin," Clin. Lab. Hematol. 23:71-80, 2001
	A48	Kishore, B.K., "Mechanism of the thesaurismosis and altered lysosomal dynamics induced by poly-D-glutamic acid in kidney proximal tubular cells," Lab. Invest. 74:1025-1037, 1996
	A49	Kishore, B.K., *et al.*, "Expression of renal aquaporins 1, 2, and 3 in a rat model of cisplatin-induced polyuria," Kidney Int. 58:701-711, 2000
	A50	Kishore, B.K., *et al.*, "Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis II. Comparative *in vitro* and *in vivo* studies with poly-L-aspartic, poly-L-glutamic and poly-D-glutamic acids," J. Pharmacol. Exp. Ther. 255:875-885, 1990
	A51	Kishore, B.K., *et al.*, "Poly-D-glutamic acid induces an acute lysosomal thesaurismosis of proximal tubules and a marked proliferation of interstitium in rat kidney," Lab. Invest. 74:1013-1023, 1996
	A52	Koury, S., *et al.*, "Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization," Blood 71:524-527, 1988
	A53	Koury, S., *et al.*, "Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization. Correlation with hamtocrit, renal erythropoietin mRNA and serum erythropoietin concentration," Blood 74:645-651, 1989
	A54	Krantz, S., "Erythropoietin," Blood 77:419-434, 1991
	A55	Lacombe, C., *et al.*, "The molecular biology of erythropoietin, Nephrol. Dial. Transplant 14:22-28, 1999
	A56	Lando, D.F., *et al.*, "Aspargine hydroxylation of HIF alpha transactivation domain: a hypoxic switch," Science 295:858-861, 2002
	A57	Le Hir, *et al.*, "Distribution of 5'-nucleotides in the renal interstitium of the rat," Cell Tissue Res. 258:177-182, 1989
	A58	Maxwell, *et al.*, "The interstitial response to renal injury: fibroblast-like cells show phenotypic changes and have reduced potential for erythropoietin gene expression, Kidney Int., 52:715-724, 1997
	A59	Maxwell, *et al.*, "Identification of the renal erythropoietin producing cells using transgenic mice," Kidney Int. 44:1149-1162, 1993
	A60	Priyadarshi, A., *et al.*, "Effects of reduction of renal mass on renal oxygen tension and erythropoietin production in the rate," Kidney Int. 61:542-546, 2002
	A61	Ribatti, D., "Human erythropoietin induces a pro-angiogenic phenotype in cultered endothelial cells and stimulates neovascularization *in vivo*," Blood 93:2627-2636, 1999
	A62	Schena, F.P, "Cytokine network and resident renal cells in glomerular diseases. Nephol. Dial. Transplant 14 [Suppl 1]:22-26, 1992
/S.H./	A63	Schuster, S., *et al.*, "Cellular sites of extra renal and renal erythropoietin production in anaemic rats," Brit. J. Hemat. 81:153-159, 1992

Examiner Signature:	Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/552,568
Filing Date	October 11, 2005
First Named Inventor	Kishore, *et al.*
Group Art Unit	1651
Examiner Name	Unassigned

NON-PATENT DOCUMENTS

Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, PuAlisher, Relevant Pages, Date and Place of PuAlication)
/S.H./	A64	Shih, S.C., *et al.*, "Hypoxia-mediated regulation of gene expression in mammalian cells," Int. J. Exp. Pathol. 79:347-357, 1998
	A65	Todd, *et al.* Poly-L-Aspartic Acid Protects Cultured Human Proximal Tubule Cells Against Aminoglycoside-Induced Electrophysiological Alterations, Toxicology Lett. Vol. 90, Nos. 2 and 3:217-221, see Figures 1 and 2, 1997
	A66	von Kooten, C., *et al.*, "Role of tubular cells in progressive renal disease," Kidney Blood Press. Res. 22:53-61, 1999
	A67	Westenfelder, C., "Unexpected renal actions of erythropoietin," Exp. Nephrol. 10:294-298, 2002
	A68	Westenfelder, C., *et al.*, "Erythropoietin stimulates proliferation of human renal carcinoma cells," Kidney Int. 58:647-657, 2000
	A69	Westenfelder, C., *et al.*, "Erythropoietin treatment ameliorates ischemic acute renal failure in rats by its anti-apoptotic, motogenic and mitogenic actions, J. Am. Soc. Nephrol 12:793A, 2001
	A70	Westenfelder, C.,*et al.*, "Human, rat and mouse kidney cells express functional erythropoietin receptors," Kidney Int. 55:808-820, 1999
	A71	Westenfelder, C., *et al.*, "Dual roles of NFkB in ischemic acture renal fauilure in rats: (1) mediates maladaptive suppression of erythropoietin (EPO) gene, (2) mediate EPO's anti-apoptotic effects in proximal tubular cells. Abstract #T323 accepted for presentation at the World Congress of Nephrology, Berlin, June 8-12, 2003
	A72	Wolf, G., *et al.*, "Molecular mechanisms of tubulointerstitial hypertrophy and hyperplasia, Kidney Int. 39:401-420, 1991
	A73	Youssoufian, H., *et al.*, "Structure, function, and activation of the erythropoietin receptor," Blood 81:2223-2236, 1993
/S.H./	A74	Zoja, C., *et al.*," Protein overload activates proximal tubular cells to release vasoactiove and inflammatory mediators," Exp. Nephrol. 7:420-428, 1999

Examiner Signature: /Susan Hanley/	Date Considered: 03/06/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.